nodes	percent_of_prediction	percent_of_DWPC	metapath
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—LNPEP—type 2 diabetes mellitus	0.0121	0.0745	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cross-presentation of soluble exogenous antigens (endosomes)—PSMD6—type 2 diabetes mellitus	0.00986	0.0605	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—FCGR activation—SRC—type 2 diabetes mellitus	0.00886	0.0544	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—UBE2E2—type 2 diabetes mellitus	0.00884	0.0543	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Role of phospholipids in phagocytosis—PIK3R1—type 2 diabetes mellitus	0.0071	0.0436	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—PSMD6—type 2 diabetes mellitus	0.00655	0.0402	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—PTPN1—type 2 diabetes mellitus	0.00639	0.0393	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—CYBA—type 2 diabetes mellitus	0.00635	0.039	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—LNPEP—type 2 diabetes mellitus	0.00485	0.0297	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—UBE2E2—type 2 diabetes mellitus	0.00438	0.0269	CbGpPWpGaD
Methyl aminolevulinate—Urticaria—Tolbutamide—type 2 diabetes mellitus	0.00424	0.00506	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Antigen processing-Cross presentation—CD36—type 2 diabetes mellitus	0.00424	0.026	CbGpPWpGaD
Methyl aminolevulinate—Eye disorder—Glipizide—type 2 diabetes mellitus	0.00423	0.00506	CcSEcCtD
Methyl aminolevulinate—Fatigue—Tolazamide—type 2 diabetes mellitus	0.00418	0.005	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Pioglitazone—type 2 diabetes mellitus	0.00406	0.00485	CcSEcCtD
Methyl aminolevulinate—Swelling—Irbesartan—type 2 diabetes mellitus	0.00405	0.00484	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Glyburide—type 2 diabetes mellitus	0.00398	0.00475	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon gamma signaling—ICAM1—type 2 diabetes mellitus	0.00395	0.0243	CbGpPWpGaD
Methyl aminolevulinate—Erythema—Glipizide—type 2 diabetes mellitus	0.00394	0.00471	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Sitagliptin—type 2 diabetes mellitus	0.00394	0.00471	CcSEcCtD
Methyl aminolevulinate—Oedema—Repaglinide—type 2 diabetes mellitus	0.00389	0.00465	CcSEcCtD
Methyl aminolevulinate—Fatigue—Nateglinide—type 2 diabetes mellitus	0.00388	0.00463	CcSEcCtD
Methyl aminolevulinate—Urticaria—Tolazamide—type 2 diabetes mellitus	0.00385	0.00461	CcSEcCtD
Methyl aminolevulinate—Urticaria—Chlorpropamide—type 2 diabetes mellitus	0.00385	0.00461	CcSEcCtD
Methyl aminolevulinate—Urticaria—Linagliptin—type 2 diabetes mellitus	0.00382	0.00456	CcSEcCtD
Methyl aminolevulinate—Swelling—Losartan—type 2 diabetes mellitus	0.00381	0.00455	CcSEcCtD
Methyl aminolevulinate—Pruritus—Tolbutamide—type 2 diabetes mellitus	0.00377	0.00451	CcSEcCtD
Methyl aminolevulinate—Rash—Miglitol—type 2 diabetes mellitus	0.00374	0.00447	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Miglitol—type 2 diabetes mellitus	0.00374	0.00446	CcSEcCtD
Methyl aminolevulinate—Urticaria—Acarbose—type 2 diabetes mellitus	0.0037	0.00442	CcSEcCtD
Methyl aminolevulinate—Erythema—Glimepiride—type 2 diabetes mellitus	0.00368	0.0044	CcSEcCtD
Methyl aminolevulinate—Oedema—Rosiglitazone—type 2 diabetes mellitus	0.00368	0.00439	CcSEcCtD
Methyl aminolevulinate—Infection—Rosiglitazone—type 2 diabetes mellitus	0.00365	0.00436	CcSEcCtD
Methyl aminolevulinate—Urticaria—Nateglinide—type 2 diabetes mellitus	0.00357	0.00427	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Gliclazide—type 2 diabetes mellitus	0.00357	0.00427	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Bromocriptine—type 2 diabetes mellitus	0.00357	0.00426	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Linagliptin—type 2 diabetes mellitus	0.00354	0.00423	CcSEcCtD
Methyl aminolevulinate—Nausea—Miglitol—type 2 diabetes mellitus	0.00352	0.00421	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Repaglinide—type 2 diabetes mellitus	0.00349	0.00417	CcSEcCtD
Methyl aminolevulinate—Asthenia—Tolazamide—type 2 diabetes mellitus	0.00348	0.00416	CcSEcCtD
Methyl aminolevulinate—Face oedema—Irbesartan—type 2 diabetes mellitus	0.00345	0.00412	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Acarbose—type 2 diabetes mellitus	0.00343	0.0041	CcSEcCtD
Methyl aminolevulinate—Pruritus—Chlorpropamide—type 2 diabetes mellitus	0.00343	0.0041	CcSEcCtD
Methyl aminolevulinate—Pruritus—Tolazamide—type 2 diabetes mellitus	0.00343	0.0041	CcSEcCtD
Methyl aminolevulinate—Rash—Tolbutamide—type 2 diabetes mellitus	0.00336	0.00402	CcSEcCtD
Methyl aminolevulinate—Headache—Tolbutamide—type 2 diabetes mellitus	0.00334	0.00399	CcSEcCtD
Methyl aminolevulinate—Discomfort—Glipizide—type 2 diabetes mellitus	0.00332	0.00396	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Nateglinide—type 2 diabetes mellitus	0.00331	0.00396	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Valsartan—type 2 diabetes mellitus	0.00328	0.00392	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Glyburide—type 2 diabetes mellitus	0.00326	0.00389	CcSEcCtD
Methyl aminolevulinate—Face oedema—Losartan—type 2 diabetes mellitus	0.00325	0.00388	CcSEcCtD
Methyl aminolevulinate—Asthenia—Nateglinide—type 2 diabetes mellitus	0.00323	0.00385	CcSEcCtD
Methyl aminolevulinate—Oedema—Glipizide—type 2 diabetes mellitus	0.00322	0.00385	CcSEcCtD
Methyl aminolevulinate—Dizziness—Tolazamide—type 2 diabetes mellitus	0.00321	0.00383	CcSEcCtD
Methyl aminolevulinate—Dizziness—Chlorpropamide—type 2 diabetes mellitus	0.00321	0.00383	CcSEcCtD
Methyl aminolevulinate—Pruritus—Nateglinide—type 2 diabetes mellitus	0.00318	0.0038	CcSEcCtD
Methyl aminolevulinate—Discomfort—Pioglitazone—type 2 diabetes mellitus	0.00318	0.0038	CcSEcCtD
Methyl aminolevulinate—Fatigue—Rosiglitazone—type 2 diabetes mellitus	0.00317	0.00379	CcSEcCtD
Methyl aminolevulinate—Nausea—Tolbutamide—type 2 diabetes mellitus	0.00317	0.00378	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—PTPN1—type 2 diabetes mellitus	0.00312	0.0192	CbGpPWpGaD
Methyl aminolevulinate—Urticaria—Repaglinide—type 2 diabetes mellitus	0.00309	0.00369	CcSEcCtD
Methyl aminolevulinate—Discomfort—Sitagliptin—type 2 diabetes mellitus	0.00309	0.00369	CcSEcCtD
Methyl aminolevulinate—Oedema—Pioglitazone—type 2 diabetes mellitus	0.00308	0.00368	CcSEcCtD
Methyl aminolevulinate—Infection—Pioglitazone—type 2 diabetes mellitus	0.00306	0.00366	CcSEcCtD
Methyl aminolevulinate—Rash—Tolazamide—type 2 diabetes mellitus	0.00306	0.00365	CcSEcCtD
Methyl aminolevulinate—Rash—Chlorpropamide—type 2 diabetes mellitus	0.00306	0.00365	CcSEcCtD
Methyl aminolevulinate—Headache—Tolazamide—type 2 diabetes mellitus	0.00304	0.00363	CcSEcCtD
Methyl aminolevulinate—Headache—Chlorpropamide—type 2 diabetes mellitus	0.00304	0.00363	CcSEcCtD
Methyl aminolevulinate—Erythema—Glyburide—type 2 diabetes mellitus	0.00304	0.00363	CcSEcCtD
Methyl aminolevulinate—Rash—Linagliptin—type 2 diabetes mellitus	0.00303	0.00362	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Linagliptin—type 2 diabetes mellitus	0.00303	0.00361	CcSEcCtD
Methyl aminolevulinate—Headache—Linagliptin—type 2 diabetes mellitus	0.00301	0.00359	CcSEcCtD
Methyl aminolevulinate—Infection—Sitagliptin—type 2 diabetes mellitus	0.00298	0.00355	CcSEcCtD
Methyl aminolevulinate—Dizziness—Nateglinide—type 2 diabetes mellitus	0.00297	0.00355	CcSEcCtD
Methyl aminolevulinate—Rash—Acarbose—type 2 diabetes mellitus	0.00294	0.00351	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Acarbose—type 2 diabetes mellitus	0.00294	0.00351	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Gliclazide—type 2 diabetes mellitus	0.00293	0.0035	CcSEcCtD
Methyl aminolevulinate—Urticaria—Rosiglitazone—type 2 diabetes mellitus	0.00292	0.00349	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Glipizide—type 2 diabetes mellitus	0.00289	0.00345	CcSEcCtD
Methyl aminolevulinate—Nausea—Chlorpropamide—type 2 diabetes mellitus	0.00288	0.00344	CcSEcCtD
Methyl aminolevulinate—Nausea—Tolazamide—type 2 diabetes mellitus	0.00288	0.00344	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Repaglinide—type 2 diabetes mellitus	0.00287	0.00342	CcSEcCtD
Methyl aminolevulinate—Rash—Nateglinide—type 2 diabetes mellitus	0.00283	0.00339	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Nateglinide—type 2 diabetes mellitus	0.00283	0.00338	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—TRPC1—type 2 diabetes mellitus	0.00282	0.0173	CbGpPWpGaD
Methyl aminolevulinate—Photosensitivity reaction—Irbesartan—type 2 diabetes mellitus	0.00282	0.00337	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—PIK3R1—type 2 diabetes mellitus	0.00277	0.017	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Acarbose—type 2 diabetes mellitus	0.00277	0.00331	CcSEcCtD
Methyl aminolevulinate—Pain—Glipizide—type 2 diabetes mellitus	0.00275	0.00329	CcSEcCtD
Methyl aminolevulinate—Pruritus—Repaglinide—type 2 diabetes mellitus	0.00275	0.00329	CcSEcCtD
Methyl aminolevulinate—Erythema—Gliclazide—type 2 diabetes mellitus	0.00273	0.00326	CcSEcCtD
Methyl aminolevulinate—Oedema—Bromocriptine—type 2 diabetes mellitus	0.00271	0.00324	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Glimepiride—type 2 diabetes mellitus	0.0027	0.00322	CcSEcCtD
Methyl aminolevulinate—Infection—Bromocriptine—type 2 diabetes mellitus	0.00269	0.00322	CcSEcCtD
Methyl aminolevulinate—Nausea—Nateglinide—type 2 diabetes mellitus	0.00267	0.00319	CcSEcCtD
Methyl aminolevulinate—Fatigue—Pioglitazone—type 2 diabetes mellitus	0.00266	0.00318	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—UBE2E2—type 2 diabetes mellitus	0.00266	0.0163	CbGpPWpGaD
Methyl aminolevulinate—Photosensitivity reaction—Losartan—type 2 diabetes mellitus	0.00265	0.00317	CcSEcCtD
Methyl aminolevulinate—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.00264	0.00315	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—DEFB1—type 2 diabetes mellitus	0.00262	0.0161	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—PSMD6—type 2 diabetes mellitus	0.00262	0.0161	CbGpPWpGaD
Methyl aminolevulinate—Pruritus—Rosiglitazone—type 2 diabetes mellitus	0.0026	0.00311	CcSEcCtD
Methyl aminolevulinate—Fatigue—Glimepiride—type 2 diabetes mellitus	0.00259	0.00309	CcSEcCtD
Methyl aminolevulinate—Fatigue—Sitagliptin—type 2 diabetes mellitus	0.00258	0.00308	CcSEcCtD
Methyl aminolevulinate—Pain—Sitagliptin—type 2 diabetes mellitus	0.00256	0.00306	CcSEcCtD
Methyl aminolevulinate—Urticaria—Glipizide—type 2 diabetes mellitus	0.00256	0.00306	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—CYBA—type 2 diabetes mellitus	0.00253	0.0156	CbGpPWpGaD
Methyl aminolevulinate—Oedema—Glyburide—type 2 diabetes mellitus	0.00248	0.00296	CcSEcCtD
Methyl aminolevulinate—Rash—Repaglinide—type 2 diabetes mellitus	0.00245	0.00293	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Repaglinide—type 2 diabetes mellitus	0.00245	0.00293	CcSEcCtD
Methyl aminolevulinate—Urticaria—Pioglitazone—type 2 diabetes mellitus	0.00245	0.00293	CcSEcCtD
Methyl aminolevulinate—Eye disorder—Metformin—type 2 diabetes mellitus	0.00245	0.00292	CcSEcCtD
Methyl aminolevulinate—Headache—Repaglinide—type 2 diabetes mellitus	0.00244	0.00291	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Bromocriptine—type 2 diabetes mellitus	0.00243	0.00291	CcSEcCtD
Methyl aminolevulinate—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.00243	0.00291	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—LNPEP—type 2 diabetes mellitus	0.0024	0.0147	CbGpPWpGaD
Methyl aminolevulinate—Urticaria—Glimepiride—type 2 diabetes mellitus	0.00239	0.00285	CcSEcCtD
Methyl aminolevulinate—Urticaria—Sitagliptin—type 2 diabetes mellitus	0.00238	0.00284	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Glipizide—type 2 diabetes mellitus	0.00237	0.00283	CcSEcCtD
Methyl aminolevulinate—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.00234	0.00279	CcSEcCtD
Methyl aminolevulinate—Rash—Rosiglitazone—type 2 diabetes mellitus	0.00232	0.00277	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Rosiglitazone—type 2 diabetes mellitus	0.00232	0.00277	CcSEcCtD
Methyl aminolevulinate—Nausea—Repaglinide—type 2 diabetes mellitus	0.00231	0.00276	CcSEcCtD
Methyl aminolevulinate—Asthenia—Glipizide—type 2 diabetes mellitus	0.00231	0.00276	CcSEcCtD
Methyl aminolevulinate—Headache—Rosiglitazone—type 2 diabetes mellitus	0.0023	0.00275	CcSEcCtD
Methyl aminolevulinate—Discomfort—Gliclazide—type 2 diabetes mellitus	0.00229	0.00274	CcSEcCtD
Methyl aminolevulinate—Erythema—Metformin—type 2 diabetes mellitus	0.00228	0.00272	CcSEcCtD
Methyl aminolevulinate—Pruritus—Glipizide—type 2 diabetes mellitus	0.00228	0.00272	CcSEcCtD
Methyl aminolevulinate—Photosensitivity reaction—Ramipril—type 2 diabetes mellitus	0.00228	0.00272	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Pioglitazone—type 2 diabetes mellitus	0.00227	0.00271	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Glyburide—type 2 diabetes mellitus	0.00222	0.00266	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Glimepiride—type 2 diabetes mellitus	0.00221	0.00264	CcSEcCtD
Methyl aminolevulinate—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.00221	0.00264	CcSEcCtD
Methyl aminolevulinate—Infection—Gliclazide—type 2 diabetes mellitus	0.00221	0.00264	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Sitagliptin—type 2 diabetes mellitus	0.00221	0.00264	CcSEcCtD
Methyl aminolevulinate—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.00218	0.00261	CcSEcCtD
Methyl aminolevulinate—Asthenia—Glimepiride—type 2 diabetes mellitus	0.00216	0.00257	CcSEcCtD
Methyl aminolevulinate—Urticaria—Bromocriptine—type 2 diabetes mellitus	0.00215	0.00257	CcSEcCtD
Methyl aminolevulinate—Erythema—Irbesartan—type 2 diabetes mellitus	0.00215	0.00257	CcSEcCtD
Methyl aminolevulinate—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.00215	0.00257	CcSEcCtD
Methyl aminolevulinate—Dizziness—Glipizide—type 2 diabetes mellitus	0.00213	0.00254	CcSEcCtD
Methyl aminolevulinate—Pruritus—Glimepiride—type 2 diabetes mellitus	0.00213	0.00254	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—PTPN1—type 2 diabetes mellitus	0.00209	0.0128	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Orlistat—type 2 diabetes mellitus	0.00208	0.00249	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Fcgamma receptor (FCGR) dependent phagocytosis—SRC—type 2 diabetes mellitus	0.00205	0.0126	CbGpPWpGaD
Methyl aminolevulinate—Oedema—Valsartan—type 2 diabetes mellitus	0.00204	0.00244	CcSEcCtD
Methyl aminolevulinate—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.00204	0.00244	CcSEcCtD
Methyl aminolevulinate—Infection—Valsartan—type 2 diabetes mellitus	0.00203	0.00243	CcSEcCtD
Methyl aminolevulinate—Rash—Glipizide—type 2 diabetes mellitus	0.00203	0.00242	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Glipizide—type 2 diabetes mellitus	0.00203	0.00242	CcSEcCtD
Methyl aminolevulinate—Erythema—Losartan—type 2 diabetes mellitus	0.00203	0.00242	CcSEcCtD
Methyl aminolevulinate—Oedema—Orlistat—type 2 diabetes mellitus	0.00202	0.00241	CcSEcCtD
Methyl aminolevulinate—Headache—Glipizide—type 2 diabetes mellitus	0.00202	0.00241	CcSEcCtD
Methyl aminolevulinate—Infection—Orlistat—type 2 diabetes mellitus	0.00201	0.0024	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Gliclazide—type 2 diabetes mellitus	0.002	0.00239	CcSEcCtD
Methyl aminolevulinate—Dizziness—Glimepiride—type 2 diabetes mellitus	0.00199	0.00237	CcSEcCtD
Methyl aminolevulinate—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.00198	0.00237	CcSEcCtD
Methyl aminolevulinate—Urticaria—Glyburide—type 2 diabetes mellitus	0.00197	0.00235	CcSEcCtD
Methyl aminolevulinate—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.00194	0.00232	CcSEcCtD
Methyl aminolevulinate—Headache—Pioglitazone—type 2 diabetes mellitus	0.00193	0.00231	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Interferon Signaling—ICAM1—type 2 diabetes mellitus	0.00193	0.0118	CbGpPWpGaD
Methyl aminolevulinate—Discomfort—Metformin—type 2 diabetes mellitus	0.00192	0.00229	CcSEcCtD
Methyl aminolevulinate—Fatigue—Gliclazide—type 2 diabetes mellitus	0.00192	0.00229	CcSEcCtD
Methyl aminolevulinate—Nausea—Glipizide—type 2 diabetes mellitus	0.00191	0.00228	CcSEcCtD
Methyl aminolevulinate—Pain—Gliclazide—type 2 diabetes mellitus	0.0019	0.00227	CcSEcCtD
Methyl aminolevulinate—Rash—Glimepiride—type 2 diabetes mellitus	0.00189	0.00226	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.00189	0.00226	CcSEcCtD
Methyl aminolevulinate—Rash—Sitagliptin—type 2 diabetes mellitus	0.00189	0.00226	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.00189	0.00225	CcSEcCtD
Methyl aminolevulinate—Headache—Glimepiride—type 2 diabetes mellitus	0.00188	0.00225	CcSEcCtD
Methyl aminolevulinate—Headache—Sitagliptin—type 2 diabetes mellitus	0.00188	0.00224	CcSEcCtD
Methyl aminolevulinate—Oedema—Metformin—type 2 diabetes mellitus	0.00186	0.00222	CcSEcCtD
Methyl aminolevulinate—Infection—Metformin—type 2 diabetes mellitus	0.00185	0.00221	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.00184	0.00219	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Glyburide—type 2 diabetes mellitus	0.00183	0.00218	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.00181	0.00217	CcSEcCtD
Methyl aminolevulinate—Discomfort—Irbesartan—type 2 diabetes mellitus	0.00181	0.00216	CcSEcCtD
Methyl aminolevulinate—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.00179	0.00214	CcSEcCtD
Methyl aminolevulinate—Nausea—Glimepiride—type 2 diabetes mellitus	0.00178	0.00213	CcSEcCtD
Methyl aminolevulinate—Nausea—Sitagliptin—type 2 diabetes mellitus	0.00178	0.00212	CcSEcCtD
Methyl aminolevulinate—Asthenia—Glyburide—type 2 diabetes mellitus	0.00178	0.00212	CcSEcCtD
Methyl aminolevulinate—Urticaria—Gliclazide—type 2 diabetes mellitus	0.00177	0.00211	CcSEcCtD
Methyl aminolevulinate—Fatigue—Valsartan—type 2 diabetes mellitus	0.00176	0.00211	CcSEcCtD
Methyl aminolevulinate—Oedema—Irbesartan—type 2 diabetes mellitus	0.00176	0.0021	CcSEcCtD
Methyl aminolevulinate—Pruritus—Glyburide—type 2 diabetes mellitus	0.00175	0.00209	CcSEcCtD
Methyl aminolevulinate—Infection—Irbesartan—type 2 diabetes mellitus	0.00175	0.00208	CcSEcCtD
Methyl aminolevulinate—Fatigue—Orlistat—type 2 diabetes mellitus	0.00174	0.00208	CcSEcCtD
Methyl aminolevulinate—Erythema—Ramipril—type 2 diabetes mellitus	0.00174	0.00207	CcSEcCtD
Methyl aminolevulinate—Pain—Orlistat—type 2 diabetes mellitus	0.00173	0.00206	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—TRPC1—type 2 diabetes mellitus	0.00171	0.0105	CbGpPWpGaD
Methyl aminolevulinate—Rash—Bromocriptine—type 2 diabetes mellitus	0.00171	0.00204	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.00171	0.00204	CcSEcCtD
Methyl aminolevulinate—Discomfort—Losartan—type 2 diabetes mellitus	0.0017	0.00204	CcSEcCtD
Methyl aminolevulinate—Headache—Bromocriptine—type 2 diabetes mellitus	0.0017	0.00203	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Class I MHC mediated antigen processing & presentation—CD36—type 2 diabetes mellitus	0.00169	0.0104	CbGpPWpGaD
Methyl aminolevulinate—Paraesthesia—Metformin—type 2 diabetes mellitus	0.00167	0.002	CcSEcCtD
Methyl aminolevulinate—Oedema—Losartan—type 2 diabetes mellitus	0.00165	0.00197	CcSEcCtD
Methyl aminolevulinate—Infection—Losartan—type 2 diabetes mellitus	0.00164	0.00196	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Gliclazide—type 2 diabetes mellitus	0.00164	0.00196	CcSEcCtD
Methyl aminolevulinate—Urticaria—Valsartan—type 2 diabetes mellitus	0.00162	0.00194	CcSEcCtD
Methyl aminolevulinate—Nausea—Bromocriptine—type 2 diabetes mellitus	0.00161	0.00192	CcSEcCtD
Methyl aminolevulinate—Fatigue—Metformin—type 2 diabetes mellitus	0.0016	0.00192	CcSEcCtD
Methyl aminolevulinate—Urticaria—Orlistat—type 2 diabetes mellitus	0.0016	0.00192	CcSEcCtD
Methyl aminolevulinate—Asthenia—Gliclazide—type 2 diabetes mellitus	0.0016	0.00191	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.00158	0.00188	CcSEcCtD
Methyl aminolevulinate—Pruritus—Gliclazide—type 2 diabetes mellitus	0.00157	0.00188	CcSEcCtD
Methyl aminolevulinate—Rash—Glyburide—type 2 diabetes mellitus	0.00156	0.00187	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Glyburide—type 2 diabetes mellitus	0.00156	0.00186	CcSEcCtD
Methyl aminolevulinate—Headache—Glyburide—type 2 diabetes mellitus	0.00155	0.00185	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—DEFB1—type 2 diabetes mellitus	0.00152	0.00936	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Irbesartan—type 2 diabetes mellitus	0.00151	0.00181	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Valsartan—type 2 diabetes mellitus	0.00151	0.0018	CcSEcCtD
Methyl aminolevulinate—Pain—Irbesartan—type 2 diabetes mellitus	0.0015	0.00179	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Orlistat—type 2 diabetes mellitus	0.00149	0.00178	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Losartan—type 2 diabetes mellitus	0.00148	0.00177	CcSEcCtD
Methyl aminolevulinate—Urticaria—Metformin—type 2 diabetes mellitus	0.00148	0.00177	CcSEcCtD
Methyl aminolevulinate—Nausea—Glyburide—type 2 diabetes mellitus	0.00147	0.00176	CcSEcCtD
Methyl aminolevulinate—Dizziness—Gliclazide—type 2 diabetes mellitus	0.00147	0.00176	CcSEcCtD
Methyl aminolevulinate—Asthenia—Valsartan—type 2 diabetes mellitus	0.00147	0.00175	CcSEcCtD
Methyl aminolevulinate—Discomfort—Ramipril—type 2 diabetes mellitus	0.00146	0.00175	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Immune System—LNPEP—type 2 diabetes mellitus	0.00145	0.00893	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Orlistat—type 2 diabetes mellitus	0.00145	0.00173	CcSEcCtD
Methyl aminolevulinate—Pruritus—Valsartan—type 2 diabetes mellitus	0.00145	0.00173	CcSEcCtD
Methyl aminolevulinate—Pruritus—Orlistat—type 2 diabetes mellitus	0.00143	0.00171	CcSEcCtD
Methyl aminolevulinate—Fatigue—Losartan—type 2 diabetes mellitus	0.00143	0.0017	CcSEcCtD
Methyl aminolevulinate—Oedema—Ramipril—type 2 diabetes mellitus	0.00142	0.00169	CcSEcCtD
Methyl aminolevulinate—Pain—Losartan—type 2 diabetes mellitus	0.00141	0.00169	CcSEcCtD
Methyl aminolevulinate—Rash—Gliclazide—type 2 diabetes mellitus	0.0014	0.00168	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IRS2—type 2 diabetes mellitus	0.0014	0.00861	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis—Gliclazide—type 2 diabetes mellitus	0.0014	0.00167	CcSEcCtD
Methyl aminolevulinate—Urticaria—Irbesartan—type 2 diabetes mellitus	0.0014	0.00167	CcSEcCtD
Methyl aminolevulinate—Headache—Gliclazide—type 2 diabetes mellitus	0.00139	0.00166	CcSEcCtD
Methyl aminolevulinate—Dizziness—Valsartan—type 2 diabetes mellitus	0.00135	0.00161	CcSEcCtD
Methyl aminolevulinate—Dizziness—Orlistat—type 2 diabetes mellitus	0.00134	0.0016	CcSEcCtD
Methyl aminolevulinate—Asthenia—Metformin—type 2 diabetes mellitus	0.00134	0.0016	CcSEcCtD
Methyl aminolevulinate—Nausea—Gliclazide—type 2 diabetes mellitus	0.00132	0.00158	CcSEcCtD
Methyl aminolevulinate—Pruritus—Metformin—type 2 diabetes mellitus	0.00132	0.00157	CcSEcCtD
Methyl aminolevulinate—Urticaria—Losartan—type 2 diabetes mellitus	0.00131	0.00157	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PSMD6—type 2 diabetes mellitus	0.0013	0.00795	CbGpPWpGaD
Methyl aminolevulinate—Hypersensitivity—Irbesartan—type 2 diabetes mellitus	0.00129	0.00155	CcSEcCtD
Methyl aminolevulinate—Rash—Valsartan—type 2 diabetes mellitus	0.00129	0.00154	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—ICAM1—type 2 diabetes mellitus	0.00129	0.00791	CbGpPWpGaD
Methyl aminolevulinate—Dermatitis—Valsartan—type 2 diabetes mellitus	0.00129	0.00154	CcSEcCtD
Methyl aminolevulinate—Headache—Valsartan—type 2 diabetes mellitus	0.00128	0.00153	CcSEcCtD
Methyl aminolevulinate—Rash—Orlistat—type 2 diabetes mellitus	0.00127	0.00152	CcSEcCtD
Methyl aminolevulinate—Paraesthesia—Ramipril—type 2 diabetes mellitus	0.00127	0.00152	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Orlistat—type 2 diabetes mellitus	0.00127	0.00152	CcSEcCtD
Methyl aminolevulinate—Headache—Orlistat—type 2 diabetes mellitus	0.00127	0.00151	CcSEcCtD
Methyl aminolevulinate—Asthenia—Irbesartan—type 2 diabetes mellitus	0.00126	0.00151	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CYBA—type 2 diabetes mellitus	0.00125	0.0077	CbGpPWpGaD
Methyl aminolevulinate—Pruritus—Irbesartan—type 2 diabetes mellitus	0.00124	0.00148	CcSEcCtD
Methyl aminolevulinate—Dizziness—Metformin—type 2 diabetes mellitus	0.00123	0.00147	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IRS1—type 2 diabetes mellitus	0.00122	0.00751	CbGpPWpGaD
Methyl aminolevulinate—Fatigue—Ramipril—type 2 diabetes mellitus	0.00122	0.00146	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Losartan—type 2 diabetes mellitus	0.00122	0.00145	CcSEcCtD
Methyl aminolevulinate—Nausea—Valsartan—type 2 diabetes mellitus	0.00121	0.00145	CcSEcCtD
Methyl aminolevulinate—Nausea—Orlistat—type 2 diabetes mellitus	0.0012	0.00143	CcSEcCtD
Methyl aminolevulinate—Asthenia—Losartan—type 2 diabetes mellitus	0.00119	0.00142	CcSEcCtD
Methyl aminolevulinate—Rash—Metformin—type 2 diabetes mellitus	0.00117	0.0014	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Metformin—type 2 diabetes mellitus	0.00117	0.0014	CcSEcCtD
Methyl aminolevulinate—Pruritus—Losartan—type 2 diabetes mellitus	0.00117	0.0014	CcSEcCtD
Methyl aminolevulinate—Headache—Metformin—type 2 diabetes mellitus	0.00117	0.00139	CcSEcCtD
Methyl aminolevulinate—Dizziness—Irbesartan—type 2 diabetes mellitus	0.00116	0.00139	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—RASGRP1—type 2 diabetes mellitus	0.00115	0.00706	CbGpPWpGaD
Methyl aminolevulinate—Urticaria—Ramipril—type 2 diabetes mellitus	0.00113	0.00135	CcSEcCtD
Methyl aminolevulinate—Rash—Irbesartan—type 2 diabetes mellitus	0.00111	0.00132	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Irbesartan—type 2 diabetes mellitus	0.00111	0.00132	CcSEcCtD
Methyl aminolevulinate—Nausea—Metformin—type 2 diabetes mellitus	0.00111	0.00132	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—RASGRP1—type 2 diabetes mellitus	0.0011	0.00678	CbGpPWpGaD
Methyl aminolevulinate—Headache—Irbesartan—type 2 diabetes mellitus	0.0011	0.00131	CcSEcCtD
Methyl aminolevulinate—Dizziness—Losartan—type 2 diabetes mellitus	0.00109	0.00131	CcSEcCtD
Methyl aminolevulinate—Hypersensitivity—Ramipril—type 2 diabetes mellitus	0.00104	0.00125	CcSEcCtD
Methyl aminolevulinate—Nausea—Irbesartan—type 2 diabetes mellitus	0.00104	0.00125	CcSEcCtD
Methyl aminolevulinate—Rash—Losartan—type 2 diabetes mellitus	0.00104	0.00125	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Losartan—type 2 diabetes mellitus	0.00104	0.00124	CcSEcCtD
Methyl aminolevulinate—Headache—Losartan—type 2 diabetes mellitus	0.00104	0.00124	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—PIK3R1—type 2 diabetes mellitus	0.00103	0.00631	CbGpPWpGaD
Methyl aminolevulinate—Asthenia—Ramipril—type 2 diabetes mellitus	0.00102	0.00121	CcSEcCtD
Methyl aminolevulinate—Pruritus—Ramipril—type 2 diabetes mellitus	0.001	0.0012	CcSEcCtD
Methyl aminolevulinate—Nausea—Losartan—type 2 diabetes mellitus	0.000982	0.00117	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—RELA—type 2 diabetes mellitus	0.000967	0.00594	CbGpPWpGaD
Methyl aminolevulinate—Dizziness—Ramipril—type 2 diabetes mellitus	0.000937	0.00112	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—AGER—type 2 diabetes mellitus	0.000901	0.00553	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—ADCY5—type 2 diabetes mellitus	0.000898	0.00552	CbGpPWpGaD
Methyl aminolevulinate—Rash—Ramipril—type 2 diabetes mellitus	0.000894	0.00107	CcSEcCtD
Methyl aminolevulinate—Dermatitis—Ramipril—type 2 diabetes mellitus	0.000893	0.00107	CcSEcCtD
Methyl aminolevulinate—Headache—Ramipril—type 2 diabetes mellitus	0.000888	0.00106	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CD36—type 2 diabetes mellitus	0.000872	0.00535	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PPP2CA—type 2 diabetes mellitus	0.000861	0.00529	CbGpPWpGaD
Methyl aminolevulinate—Nausea—Ramipril—type 2 diabetes mellitus	0.000842	0.00101	CcSEcCtD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CD36—type 2 diabetes mellitus	0.000837	0.00514	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PPP2CA—type 2 diabetes mellitus	0.000827	0.00508	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—C3—type 2 diabetes mellitus	0.000826	0.00507	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—NFKB1—type 2 diabetes mellitus	0.000816	0.00501	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—C3—type 2 diabetes mellitus	0.000793	0.00487	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—BCL2L1—type 2 diabetes mellitus	0.000791	0.00486	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CRP—type 2 diabetes mellitus	0.000786	0.00483	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—IRS2—type 2 diabetes mellitus	0.000786	0.00483	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PSMD6—type 2 diabetes mellitus	0.000786	0.00482	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CALM1—type 2 diabetes mellitus	0.000772	0.00474	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CYBA—type 2 diabetes mellitus	0.000761	0.00467	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—IRS2—type 2 diabetes mellitus	0.000755	0.00463	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—CALM1—type 2 diabetes mellitus	0.000741	0.00455	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PRKCB—type 2 diabetes mellitus	0.000697	0.00428	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—ICAM1—type 2 diabetes mellitus	0.000694	0.00426	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—IRS1—type 2 diabetes mellitus	0.000686	0.00421	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PTPN1—type 2 diabetes mellitus	0.000681	0.00418	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—RASGRP1—type 2 diabetes mellitus	0.00067	0.00411	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—IRS1—type 2 diabetes mellitus	0.000659	0.00405	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—CASP8—type 2 diabetes mellitus	0.000647	0.00397	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—AKT2—type 2 diabetes mellitus	0.000635	0.0039	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—AKT2—type 2 diabetes mellitus	0.00061	0.00374	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—PIK3R1—type 2 diabetes mellitus	0.000576	0.00354	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—BCL2—type 2 diabetes mellitus	0.000555	0.00341	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—PIK3R1—type 2 diabetes mellitus	0.000553	0.0034	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—RELA—type 2 diabetes mellitus	0.000542	0.00333	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—AGER—type 2 diabetes mellitus	0.000525	0.00322	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—ADCY5—type 2 diabetes mellitus	0.000523	0.00321	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—RELA—type 2 diabetes mellitus	0.000521	0.0032	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Cytokine Signaling in Immune system—IL6—type 2 diabetes mellitus	0.000512	0.00314	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CD36—type 2 diabetes mellitus	0.000508	0.00312	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PPP2CA—type 2 diabetes mellitus	0.000501	0.00308	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—C3—type 2 diabetes mellitus	0.000481	0.00295	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—BCL2L1—type 2 diabetes mellitus	0.000461	0.00283	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CRP—type 2 diabetes mellitus	0.000458	0.00281	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IRS2—type 2 diabetes mellitus	0.000458	0.00281	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—NFKB1—type 2 diabetes mellitus	0.000457	0.00281	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CALM1—type 2 diabetes mellitus	0.00045	0.00276	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—NFKB1—type 2 diabetes mellitus	0.000439	0.0027	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—SRC—type 2 diabetes mellitus	0.000426	0.00262	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PRKCB—type 2 diabetes mellitus	0.000422	0.00259	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—ICAM1—type 2 diabetes mellitus	0.000421	0.00258	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—SRC—type 2 diabetes mellitus	0.000409	0.00251	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IRS1—type 2 diabetes mellitus	0.0004	0.00245	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—CASP8—type 2 diabetes mellitus	0.000377	0.00231	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—EGFR—type 2 diabetes mellitus	0.000374	0.00229	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—AKT2—type 2 diabetes mellitus	0.00037	0.00227	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—EGFR—type 2 diabetes mellitus	0.000359	0.0022	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—PIK3R1—type 2 diabetes mellitus	0.000336	0.00206	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—BCL2—type 2 diabetes mellitus	0.000323	0.00198	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—RELA—type 2 diabetes mellitus	0.000316	0.00194	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—IL6—type 2 diabetes mellitus	0.000287	0.00176	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—NFKB1—type 2 diabetes mellitus	0.000266	0.00164	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Innate Immune System—AKT1—type 2 diabetes mellitus	0.000265	0.00163	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Adaptive Immune System—AKT1—type 2 diabetes mellitus	0.000254	0.00156	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—SRC—type 2 diabetes mellitus	0.000248	0.00152	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—EGFR—type 2 diabetes mellitus	0.000218	0.00134	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—IL6—type 2 diabetes mellitus	0.000167	0.00103	CbGpPWpGaD
Methyl aminolevulinate—FCGR1A—Immune System—AKT1—type 2 diabetes mellitus	0.000154	0.000947	CbGpPWpGaD
